Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02868268 · ClinicalTrials.gov registry record

Neuroblastoma Precision Trial

A clinical trial of Neuroblastoma, sponsored by New Approaches to Neuroblastoma Therapy Consortium.

Active
Registry status
93
Enrollment target
11
Study locations

NCT02868268 is a study of Neuroblastoma that is active but no longer recruiting, run by New Approaches to Neuroblastoma Therapy Consortium. The registered enrollment target is 93 participants, below the 238-participant average among 94 other Neuroblastoma trials with a reported enrollment target (61% lower). The trial reports 11 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02868268, a study of Neuroblastoma, is active but no longer recruiting, sponsored by New Approaches to Neuroblastoma Therapy Consortium.

ACTIVE NOT RECRUITING
Registry status
93 participants
Enrollment target
11
Study locations

Study Summary

This proposal sets forth the platform for a Precision Medicine clinical trial through the New Approaches to Neuroblastoma Therapy (NANT) consortium. The plan is to utilize NANT's established multi-institutional infrastructure and Translational Genomics Research Institute GEM sequencing platform for acquisition and gene panel sequencing of relapsed biological specimens in relapsed/refractory neuroblastoma (rNB) including those obtained from the bone, bone marrow or soft tissue. Our primary aim is to identify subgroups of rNB patients who have potentially targetable genetic (ALK, MAPK pathway, Metabolic-related genes) and/or immunologic (tumor-associated macrophage infiltration and/or programmed death ligand \[PD-L1\] expression) biomarkers in rNB. Additional potential novel biomarkers will also be evaluated and reported in this cohort of patients.

Conditions Studied

Neuroblastoma

Interventions

  • OTHER Gene panel sequencing of tumor specimens

Study Locations (11)

California

  • Children's Hospital Los Angeles - Los Angeles
  • UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco

Colorado

  • Children Hospital of Colorado - Aurora

Georgia

  • Children's Healthcare of Atlanta - Atlanta

Illinois

  • Children's Memorial Hospital - Chicago - Chicago

Massachusetts

  • Childrens Hospital Boston, Dana-Farber Cancer Institute. - Boston

Michigan

  • C.S Mott Children's Hospital - Ann Arbor

North Carolina

  • University of North Carolina - Chapel Hill

Ohio

  • Cincinnati Children's Hospital Medical Center - Cincinnati

Trial Details

FieldValue
Enrollment Target 93 participants
Start Date 2016-08-22
Est. Completion 2026-12

Sponsor

New Approaches to Neuroblastoma Therapy Consortium

23 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02868268

The ClinicalTrials.gov registry entry for NCT02868268 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 93 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 238-participant average among 94 other Neuroblastoma trials with a reported enrollment target (61% lower). The listed sponsor is New Approaches to Neuroblastoma Therapy Consortium, which has 23 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Neuroblastoma appearing as the primary indexed condition, and to 1 intervention - of which Gene panel sequencing of tumor specimens is the first listed.

NCT02868268 reports 11 study locations spanning 10 distinct geographic areas - top geographies include California, Colorado, Georgia.

Frequently Asked Questions

What is clinical trial NCT02868268 about?

NCT02868268 is a clinical study titled "Neuroblastoma Precision Trial". This proposal sets forth the platform for a Precision Medicine clinical trial through the New Approaches to Neuroblastoma Therapy (NANT) consortium. The plan is to utilize NANT's established multi-institutional infrastructure and Translational Genomics Research Institute GEM sequencing platform for ...

What is the current status of trial NCT02868268?

This trial is currently active not recruiting. The enrollment target is 93 participants. The study started on 2016-08-22. Estimated completion is 2026-12.

What conditions does trial NCT02868268 study?

This clinical trial studies the following conditions: Neuroblastoma.

What interventions are being tested in trial NCT02868268?

The interventions under investigation include: Gene panel sequencing of tumor specimens (OTHER).

Who is sponsoring clinical trial NCT02868268?

This trial is sponsored by New Approaches to Neuroblastoma Therapy Consortium, which has 23 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02868268 being conducted?

This trial has 11 study locations across California, Colorado, Georgia, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Neuroblastoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Neuroblastoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.